These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 23674316)

  • 1. The role of noninvasive prenatal testing as a diagnostic versus a screening tool--a cost-effectiveness analysis.
    Ohno M; Caughey A
    Prenat Diagn; 2013 Jul; 33(7):630-5. PubMed ID: 23674316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis.
    Beulen L; Grutters JP; Faas BH; Feenstra I; van Vugt JM; Bekker MN
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():53-61. PubMed ID: 25238658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies.
    O'Leary P; Maxwell S; Murch A; Hendrie D
    Aust N Z J Obstet Gynaecol; 2013 Oct; 53(5):425-33. PubMed ID: 24090461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uptake of noninvasive prenatal testing at a large academic referral center.
    Larion S; Warsof SL; Romary L; Mlynarczyk M; Peleg D; Abuhamad AZ
    Am J Obstet Gynecol; 2014 Dec; 211(6):651.e1-7. PubMed ID: 24954652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program.
    Ayres AC; Whitty JA; Ellwood DA
    Aust N Z J Obstet Gynaecol; 2014 Oct; 54(5):412-7. PubMed ID: 25196262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of prenatal screening and diagnostic strategies for Down syndrome: A microsimulation modeling analysis.
    Zhang W; Mohammadi T; Sou J; Anis AH
    PLoS One; 2019; 14(12):e0225281. PubMed ID: 31800591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis.
    Cuckle H; Benn P; Pergament E
    Prenat Diagn; 2013 Jul; 33(7):636-42. PubMed ID: 23674341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
    Dick PT
    CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years.
    Biggio JR; Morris TC; Owen J; Stringer JS
    Am J Obstet Gynecol; 2004 Mar; 190(3):721-9. PubMed ID: 15042005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down syndrome: prenatal risk assessment and diagnosis.
    Newberger DS
    Am Fam Physician; 2000 Aug; 62(4):825-32, 837-8. PubMed ID: 10969860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninvasive prenatal testing: impact on genetic counseling, invasive prenatal diagnosis, and trisomy 21 detection.
    Wax JR; Cartin A; Chard R; Lucas FL; Pinette MG
    J Clin Ultrasound; 2015 Jan; 43(1):1-6. PubMed ID: 25303161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive prenatal detection of aneuploidy.
    Robinson C; van den Boom D; Bombard AT
    Clin Obstet Gynecol; 2014 Mar; 57(1):210-25. PubMed ID: 24351443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From Down syndrome screening to noninvasive prenatal testing: 20 years' experience in Taiwan.
    Shaw SW; Chen CP; Cheng PJ
    Taiwan J Obstet Gynecol; 2013 Dec; 52(4):470-4. PubMed ID: 24411028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fetal Down syndrome screening: a cost effectiveness analysis of alternative screening programs.
    Cusick W; Vintzileos AM
    J Matern Fetal Med; 1999; 8(6):243-8. PubMed ID: 10582856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chorionic Villus Sampling, Early Amniocentesis, and Termination of Pregnancy Without Diagnostic Testing: Comparison of Fetal Risk Following Positive Non-invasive Prenatal Testing.
    Zelig CM; Knutzen DM; Ennen CS; Dolinsky BM; Napolitano PG
    J Obstet Gynaecol Can; 2016 May; 38(5):441-445.e2. PubMed ID: 27261219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis.
    Fairbrother G; Burigo J; Sharon T; Song K
    J Matern Fetal Neonatal Med; 2016; 29(7):1160-4. PubMed ID: 26000626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs and effects of prenatal screening methods for Down syndrome and neural tube defects.
    Hoogendoorn M; Evers SM; Schielen PC; van Genugten ML; de Wit GA; Ament AJ
    Community Genet; 2008; 11(6):359-67. PubMed ID: 18690004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of detection of cell-free fetal DNA in maternal plasma in the prenatal diagnosis of chromosomal abnormalities].
    Wang SJ; Gao ZY; Lu YP; Li YL; You YQ; Zhang LW; Wang LX; Xu H
    Zhonghua Fu Chan Ke Za Zhi; 2012 Nov; 47(11):808-12. PubMed ID: 23302119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First- and second-trimester evaluation of risk for Down syndrome.
    Ball RH; Caughey AB; Malone FD; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Emig D; D'Alton ME;
    Obstet Gynecol; 2007 Jul; 110(1):10-7. PubMed ID: 17601890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost utility of prenatal diagnosis and the risk-based threshold.
    Harris RA; Washington AE; Nease RF; Kuppermann M
    Lancet; 2004 Jan; 363(9405):276-82. PubMed ID: 14751700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.